Cargando…
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial
Autores principales: | Kubasch, A. S., Peterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H., Sebert, M., Chermat, F., Gloaguen, S., Puttrich, M., Cross, M., Schneider, M., Kayser, S., Schipp, D., Giagounidis, A., Tirado-Gonzalez, I., Descot, A., van de Loosdrecht, A., Weigert, A., Metzeler, K. H., Fenaux, P., Medyouf, H., Platzbecker, U., Ades, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624604/ https://www.ncbi.nlm.nih.gov/pubmed/37735558 http://dx.doi.org/10.1038/s41375-023-02029-1 |
Ejemplares similares
-
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
por: Kubasch, Anne Sophie, et al.
Publicado: (2022) -
Axl‐inhibitor bemcentinib alleviates mitochondrial dysfunction in the unilateral ureter obstruction murine model
por: Hoel, August, et al.
Publicado: (2021) -
Adaptations and Lessons in the Province of Bergamo
por: Fagiuoli, Stefano, et al.
Publicado: (2020) -
Was fehlte den Kindern von Bergamo?
por: Fabsits, Tanja
Publicado: (2020) -
Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib—a case report
por: Bumm, Caspar V., et al.
Publicado: (2020)